Should there be a moratorium on the use of cholesterol lowering drugs
G. Davey Smith,J Pekkanen +1 more
Reads0
Chats0
TLDR
An aggressive approach to cholesterol reduction features in most of the official guidelines for the primary prevention of coronary heart disease, and high percentages of the British population would become candidates for drug treatment if the guidelines currently advanced by some authorities were put into practice.Abstract:
Recent reviews of the primary prevention of coronary heart disease through lowering cholesterol concentrations have varied considerably in their evaluation of the benefits of the intervention. 1-4 The degree of disagreement is surprising as they review essentially the same data, from clinical trials of cholesterol lowering by drugs or by diet. There is agreement about a reduced risk for coronary events, but there are differing interpretations of the increase in mortality from non-cardiovascular causes that has generally been seen. Particular concern was generated by a recent meta-analysis that showed a significantly increased risk of death from accidents and violence when the results of six randomised primary prevention trials were pooled.3 Despite the uncertainty an aggressive approach to cholesterol reduction features in most of the official guidelines for the primary prevention of coronary heart disease.` In Britain the introduction of the new general practitioner contract, with its focus on health promotion, is likely to result in an increase in cholesterol testing. High percentages of the British population would become candidates for drug treatment if the guidelines currently advanced by some authorities were put into practice. For middle aged men and women with other coronary risk factors the European Atherosclerosis Society recommends a cut off level, above which the use of lipid lowering drugs should be considered,6 well below the mean population cholesterol concentration.0`'2 The entry criteria for the expanded clinical evaluation of lovastatin study (EXCEL)\"5 would include a third of the British population. 10-12read more
Citations
More filters
Journal Article
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Anders G. Olsson,Jjv McMurray,Gudmundur Thorgeirsson,C Spaulding,J Slattery,Kalevi Pyörälä,Ole Faergeman,RA Wright,Kåre Berg,Lars Wilhelmsen,Terje R. Pedersen,Tatu A. Miettinen,Harvey D. White,John Kjekshus,Michael Gnant +14 more
Journal ArticleDOI
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
J. Shepherd,Stuart M. Cobbe,Ian Ford,C. G. Isles,AR Lorimer,Peter W. Macfarlane,J. H. Mckillop,Christopher J. Packard +7 more
TL;DR: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
J Ames S Hepherd,S Tuart M. C Obbe,I An F Ord,C Hristopher G. I Sles,A. R Oss L Orimer,P Eter W. M Acfarlane,J Ames H. M C K Illop,C Hristopher J. P Ackard,S Tudy G Roup +8 more
TL;DR: In this article, a double-blind study was designed to determine whether the administration of pravastatin to men with hypercho-lesterolemia and no history of myocardial infarction correlated with the combined incidence of nonfatal mycardial in-farction and death from coronary heart disease.
Journal ArticleDOI
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
James Shepherd,Gerard J. Blauw,Michael B. Murphy,Edward L.E.M. Bollen,Brendan M. Buckley,Stuart M. Cobbe,Ian Ford,Allan Gaw,Michael E. Hyland,J. Wouter Jukema,Adriaan M. Kamper,Peter W. Macfarlane,A. Edo Meinders,John Norrie,Chris J. Packard,Ivan J. Perry,David J. Stott,Brian Sweeney,Gillian Twomey,Rudi G. J. Westendorp +19 more
TL;DR: Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals and was extended to elderly individuals the treatment strategy currently used in middle aged people.
References
More filters
Journal ArticleDOI
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
Frick Mh,O. Elo,Haapa K,Olli P. Heinonen,P. Heinsalmi,P. Helo,Jussi K. Huttunen,Kaitaniemi P,Koskinen P,Manninen +9 more
TL;DR: Results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.
Journal ArticleDOI
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
DeWitt S. Goodman,Stephen B. Hulley,Luther T. Clark,Clay Davis,Valentin Fuster,John C. LaRosa,Albert Oberman,Ernst J. Schaefer,Daniel Steinberg,W. Virgil Brown,Scott M. Grundy,Diane M. Becker,Edwin L. Bierman,Jacqueline Sooter-Bochenek,Rebecca M. Mullis,Neil J. Stone,Donald B. Hunninghake,Jacqueline M. Dunbar,Henry N. Ginsberg,D. Roger Illingworth,Harold C. Sadin,Gustav Schonfeld,James I. Cleeman,H. Bryan Brewer,Nancy D. Ernst,William T. Friedewald,Jeffrey M. Hoeg,Basil M. Rifkind,David L. Gordon +28 more
TL;DR: New guidelines for the treatment of high blood cholesterol in adults 20 years of age and over are provided and which patients should go on to have lipoprotein analysis, and which should receive cholesterol-lowering treatment on the basis of their low density lipop protein levels and status with respect to other coronary heart disease risk factors are detailed.
Journal ArticleDOI
A Co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: Report1 from the Committee of Principal Investigators
M.F. Oliver,J. A. Heady,J.N. Morris,J. Cooper,H. Geizerova,I. Gyarfas,Green K,T. Strasser,W. G. Macfie,E. Scott,M. Czukas,J. Duba,E. Ostor,D. Grafnetter,Z. Hejil,Z. Pisa,K. Uemura,G. Lamm,J. M. Thorp +18 more
TL;DR: A double-blind intervention trial to test the hypothesis that the incidence of ischaemic heart disease in middle-aged men can be reduced by lowering raised serum cholesterol levels found men with a substantial reduction of cholesterol concentration, who smoked, and also had above average blood pressure levels showed the most benefit.
Journal ArticleDOI
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
TL;DR: The association between reduction of cholesterol concentrations and deaths not related to illness warrants further investigation and the failure of cholesterol lowering to affect overall survival justifies a more cautious appraisal of the probable benefits of reducing cholesterol concentrations in the general population.